Orexin receptor

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

Retrieved on: 
Thursday, July 1, 2021
Branches of biology, Biology, G protein-coupled receptors, Orexin antagonist, Eisai, Orexin receptor, Insomnia, Orexin, Hong Kong Airlines, Sleep

TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Key Points: 
  • TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • Eisai received approval for DAYVIGO in Hong Kong on February 28, 2021, and this launch is the first for DAYVIGO in Asia outside of Japan.
  • (10)
    The anti-insomnia drug market in Hong Kong as of 2020 valued at approximately 8.4 million USD, comprising nearly 9% of the insomnia drug market in Asia (Hong Kong, India, Indonesia, Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand).
  • Sleep.

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Retrieved on: 
Wednesday, June 9, 2021
Chemical compounds, Psychoactive drugs, Branches of biology, Hypnotics, GABAA receptor positive allosteric modulators, Pyridines, Orexin antagonist, G protein-coupled receptors, Acetamides, Lemborexant, Orexin receptor, Zolpidem

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Insomnia Data 2020: US Leads in Global Insomnia Clinical Trials, Germany Leads Major European Markets and Japan Has Top Spot in Asia

Retrieved on: 
Thursday, May 21, 2020
Branches of biology, G protein-coupled receptors, Protein families, Molecular neuroscience, Orexin receptor, Orexin, RTT, gamma-Aminobutyric acid, GABAA receptor, Insomnia, Hypocretin (orexin) receptor 1, Nemorexant

It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).

Key Points: 
  • It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).
  • The approved drugs in the insomnia space target GABA-A receptor, hypocretin/orexin receptor, chloride channel 2, chloride, melatonin receptor, histamine H1 receptor, and potassium channels.
  • Germany leads the major European markets, while Japan has the top spot in Asia.
  • Takeda leads the industry sponsors with the highest overall number of clinical trials for insomnia, followed by Merck & Co.

2020 Market Spotlight: Insomnia -- Eisai Buys Out Global Rights to Lemborexant - ResearchAndMarkets.com

Retrieved on: 
Monday, March 30, 2020
Health, Pharmaceutical, Branches of biology, Chemical compounds, Psychoactive drugs, G protein-coupled receptors, Protein families, Hypnotics, Molecular neuroscience, RTT, Orexin receptor, Orexin, Insomnia, gamma-Aminobutyric acid

It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).

Key Points: 
  • It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).
  • The approved drugs in the insomnia space target GABA-A receptor, hypocretin/orexin receptor, chloride channel 2, chloride, melatonin receptor, histamine H1 receptor, and potassium channels.
  • The largest proportion of industry-sponsored drugs in active clinical development for insomnia are in Phase III, with only one drug in the NDA/BLA phase.
  • Takeda leads the industry sponsors with the highest overall number of clinical trials for insomnia, followed by Merck & Co.

Orexin Receptor Type 2, Pipeline Review, H2 2019 - Inexia Ltd, Takeda Pharmaceutical & Idorsia Pharmaceutical Ltd - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 21, 2020
Health, Pharmaceutical, G protein-coupled receptors, Branches of biology, Cell biology, Hypocretin (orexin) receptor 2, Orexin receptor, Hypocretin (orexin) receptor 1, Orexin, TCS-OX2-29, Orexin antagonist

The "Orexin Receptor Type 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Orexin Receptor Type 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene.
  • Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 8 molecules.
  • The latest report Orexin Receptor Type 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

U.S. FDA Approves Eisai's DAYVIGO™ (lemborexant) for the Treatment of Insomnia in Adult Patients

Retrieved on: 
Monday, December 23, 2019
Psychoactive drugs, Chemical compounds, Hypnotics, Branches of biology, Organofluorides, G protein-coupled receptors, Cyclopropanes, Lemborexant, Pyrimidines, Orexin antagonist, Orexin receptor, Orexin

Patients were randomized to placebo (n=325), DAYVIGO 5 mg (n=323), or DAYVIGO 10 mg (n=323) once nightly.

Key Points: 
  • Patients were randomized to placebo (n=325), DAYVIGO 5 mg (n=323), or DAYVIGO 10 mg (n=323) once nightly.
  • Patients were randomized to placebo (n=208), DAYVIGO 5 mg (n=266) or 10 mg (n=269), or active comparator (n=263) once nightly.
  • DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • Patients with Compromised Respiratory Function:
    The effect of DAYVIGO on respiratory function should be considered for patients with compromised respiratory function.